报价延迟最少15分钟:2026/04/25 04:13 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.05 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.35/-0.41
|
|
企业价值
44.12M
|
| 资产负债 |
|
每股账面净值
0.25
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment. |
